血浆囊泡定量蛋白质组学鉴定血红蛋白E/β-地中海贫血患者的新型生物标志物
本研究采用串联质谱标签标记质谱技术,比较15例血红蛋白E/β-地中海贫血患者与健康对照血浆细胞外囊泡的蛋白质组成与数量,发现α血红蛋白稳定蛋白升高倍数最高,触珠蛋白和血红素结合蛋白持续降低,组织蛋白酶S等上调,提示这些蛋白可作为溶血和炎症的潜在生物标志物。
要点
- 血红蛋白E/β-地中海贫血患者血浆细胞外囊泡中α血红蛋白稳定蛋白升高倍数最高。
- 触珠蛋白和血红素结合蛋白在患者囊泡中持续降低,与溶血状态一致。
- 组织蛋白酶S等蛋白上调,触珠蛋白、血红素结合蛋白和组织蛋白酶S可能是溶血和炎症的潜在临床相关生物标志物。
核心结论
- 成功鉴定出血红蛋白E/β-地中海贫血患者与健康个体细胞外囊泡之间一致的蛋白质数量改变。
- 触珠蛋白、血红素结合蛋白和组织蛋白酶S可能是溶血水平和炎症的潜在临床相关生物标志物。
- 监测这些血浆蛋白可能有助于地中海贫血的临床管理。
研究设计与样本
- 采用串联质谱标签标记质谱技术分析15例患者与对照血浆分离的细胞外囊泡蛋白质。
- 为减少个体间生物学变异,将随机分配的5例患者囊泡蛋白混合,与5例年龄和性别匹配的对照混合样本在3次独立实验中进行比较。
- 对6例个体患者分离的囊泡样本进行蛋白质组数据分析,并用蛋白质印迹法验证结果。
主要发现
- α血红蛋白稳定蛋白升高倍数最高。
- 过氧化氢酶、超氧化物歧化酶、T复合体蛋白、热休克蛋白、转铁蛋白受体、铁蛋白和组织蛋白酶S在患者循环囊泡中也上调。
- 触珠蛋白和血红素结合蛋白在所有数据集中患者囊泡内持续降低,与地中海贫血存在的溶血一致。
- 6例个体患者囊泡样本的蛋白质组数据分析及蛋白质印迹结果证实了上述发现。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hemoglobin E (HbE)/β-thalassemia has a wide spectrum of clinical manifestations that cannot be explained purely by its genetic background. Circulating extracellular vesicles (EVs) are one factor that likely contributes to disease severity. This study has explored the differences in protein composition and quantity between EVs from HbE/β-thalassemic patients and healthy individuals. We used tandem mass tag labeling mass spectrometry to analyze the EV proteins isolated from the plasma of 15 patients compared with the controls. To reduce biological variation between individuals, the EV proteins isolated from randomly assigned groups of 5 HbE/β-thalassemic patients were pooled and compared with 5 pooled age- and sex-matched controls in 3 separate experiments. Alpha hemoglobin-stabilizing protein had the highest fold increase. Catalase, superoxide dismutase, T-complex proteins, heat shock proteins, transferrin receptor, ferritin, and cathepsin S were also upregulated in thalassemic circulating EVs. Importantly, haptoglobin and hemopexin were consistently reduced in patients' EVs across all data sets, in keeping with the existing hemolysis that occurs in thalassemia. The proteomic data analysis of EV samples isolated from 6 individual HbE/β-thalassemic patients and western blotting results corroborated these findings. In conclusion, we have successfully identified consistent alterations of protein quantity between EVs from HbE/β-thalassemic and healthy individuals. This work highlights haptoglobin, hemopexin, and cathepsin S as potential clinically relevant biomarkers for levels of hemolysis and inflammation. Monitoring of these plasma proteins could help in the clinical management of thalassemia.
引用
- Kittivorapart J, Crew VK, Wilson MC, et al. Quantitative proteomics of plasma vesicles identify novel biomarkers for hemoglobin E/β-thalassemic patients. Blood Adv. 2018. PMID: 29365317. doi:10.1182/bloodadvances.2017011726
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。